In this context, as the literature shows evidence of the role of NETs in COVID-19, DNase I, an FDA-approved drug that degrades NETs could be proposed as a potential new candidate for COVID-19 treatment [19–21]. The gene discussed is DNASE1; the disease is COVID-19.